Harvard’s serial entrepreneur Timothy Springer has formally launched his latest venture with a $101m series A round backed by GV.

Seismic Therapeutic, a US-based immunotherapy discovery technology developer, formally launched on Wednesday with $101m in series A funding from investors including co-founder Timothy Springer, a professor at Harvard University’s Medical School.

Venture capital firm Lightspeed Venture Partners led the round, which also featured internet technology group Alphabet’s GV unit, Boxer Capital, Polaris Partners, Samsara BioCapital as well as Seismic’s other co-founders and management team.

Seismic has built a machine learning-equipped biologics development platform dubbed Impact, which incorporates structural biology, protein engineering and translational immunology to help drug developers accelerate the process of discovering therapeutic targets for autoimmune disease.

The company will use the money to take its two lead drug candidates, which target antibody and cell-mediated autoimmunity respectively, toward clinical trials and improve Impact’s machine learning capabilities.

Jo Viney, co-founder, president and chief executive of Seismic Therapeutic, said: “The…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?